Literature DB >> 12606537

A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians.

Yunhua Li Muller1, Clifton Bogardus, Oluf Pedersen, Leslie Baier.   

Abstract

Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) is a transcriptional coactivator of peroxisome proliferator-activated receptor gamma and alpha, which play important roles in adipogenesis and lipid metabolism. A single nucleotide polymorphism within the coding region of the PGC-1 gene predicts a glycine to serine substitution at amino acid 482 and has been associated with type 2 diabetes in a Danish population. In this study, we examined whether this Gly482Ser polymorphism is associated with type 2 diabetes or obesity, or metabolic predictors of these diseases, in Pima Indians. There was no association of the Gly482Ser polymorphism with either type 2 diabetes or BMI (n = 984). However, among nondiabetic Pima Indians (n = 183-201), those with the Gly/Gly genotype had a lower mean insulin secretory response to intravenous and oral glucose and a lower mean rate of lipid oxidation (over 24 h in a respiratory chamber) despite a larger mean subcutaneous abdominal adipocyte size and a higher mean plasma free fatty acid concentration. These data indicate that the Gly482Ser missense polymorphism in PGC-1 has metabolic consequences on lipid metabolism that could influence insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606537     DOI: 10.2337/diabetes.52.3.895

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  48 in total

Review 1.  Gene expression in the pathophysiology of type 2 diabetes mellitus.

Authors:  Mary-Elizabeth Patti
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

2.  The Genetic Basis of Type 2 Diabetes.

Authors:  Swapan Kumar Das; Steven C Elbein
Journal:  Cellscience       Date:  2006-04-30

Review 3.  PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes.

Authors:  S Soyal; F Krempler; H Oberkofler; W Patsch
Journal:  Diabetologia       Date:  2006-05-17       Impact factor: 10.122

4.  Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.

Authors:  I Barroso; J Luan; M S Sandhu; P W Franks; V Crowley; A J Schafer; S O'Rahilly; N J Wareham
Journal:  Diabetologia       Date:  2006-01-25       Impact factor: 10.122

5.  Mutations in TAZ/WWTR1, a co-activator of NKX2.1 and PAX8 are not a frequent cause of thyroid dysgenesis.

Authors:  A M Ferrara; L De Sanctis; G Rossi; S Capuano; G Del Prete; E Zampella; P Gianino; A Corrias; G Fenzi; M Zannini; P E Macchia
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

6.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

7.  Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.

Authors:  L Andrulionytè; J Zacharova; J-L Chiasson; M Laakso
Journal:  Diabetologia       Date:  2004-12-08       Impact factor: 10.122

8.  Colloquium paper: bioenergetics, the origins of complexity, and the ascent of man.

Authors:  Douglas C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

Review 9.  Mitochondria, bioenergetics, and the epigenome in eukaryotic and human evolution.

Authors:  D C Wallace
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2009-12-02

10.  PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene x environment interactions in children from the European Youth Heart Study.

Authors:  E C Brito; K S Vimaleswaran; S Brage; L B Andersen; L B Sardinha; N J Wareham; U Ekelund; R J F Loos; P W Franks
Journal:  Diabetologia       Date:  2009-01-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.